Roivant Sciences Ltd. ROIV
Institutional shares held
508 Million
1.26M
calls
2.52M
puts
Total value of holdings
$6.01B
$15M
calls
$29.8M
puts
Market Cap
$8.52B
704,382,976
Shares Out.
Institutional ownership
72.07%
# of Institutions
311
We take great care to ensure that the data presented and summarized in this overview for Roivant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ROIV
View all-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$798 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$796 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$655 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$504 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$428 Million0.01% of portfolio
-
Morgan Stanley New York, NY29.7MShares$359 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY22.4MShares$271 Million7.2% of portfolio
-
State Street Corp Boston, MA19.6MShares$237 Million0.01% of portfolio
-
Patient Square Capital LP Menlo Park, CA12.2MShares$148 Million52.38% of portfolio
-
Two Seas Capital LP Rye, NY9.72MShares$118 Million37.75% of portfolio
Latest Institutional Activity in ROIV
Top Purchases
Top Sells
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Transactions at ROIV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2024
|
Mayukh Sukhatme Pres&Chief Investment Officer |
SELL
Open market or private sale
|
Direct |
412,584
-2.14%
|
$4,951,008
$12.05 P/Share
|
|
Dec 18
2024
|
Mayukh Sukhatme Pres&Chief Investment Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
412,584
+2.1%
|
$1,237,752
$3.85 P/Share
|
|
Dec 03
2024
|
Mayukh Sukhatme Pres&Chief Investment Officer |
SELL
Other acquisition or disposition
|
Direct |
3,651,985
-16.24%
|
$43,823,820
$12.21 P/Share
|
|
Nov 28
2024
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,341
-0.84%
|
$28,092
$12.69 P/Share
|
|
Nov 20
2024
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.06%
|
$120,395
$11.49 P/Share
|
|
Nov 20
2024
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
100,000
-14.15%
|
$1,100,000
$11.32 P/Share
|
|
Nov 20
2024
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+12.4%
|
$300,000
$3.85 P/Share
|
|
Nov 20
2024
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-1.77%
|
$120,395
$11.49 P/Share
|
|
Nov 20
2024
|
Rakhi Kumar Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
958
-0.46%
|
$10,538
$11.49 P/Share
|
|
Oct 28
2024
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,341
-0.83%
|
$25,751
$11.84 P/Share
|
|
Oct 21
2024
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
2,303
+2.3%
|
-
|
|
Oct 21
2024
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,613
+4.07%
|
-
|
|
Oct 21
2024
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
1,231
+1.3%
|
-
|
|
Oct 21
2024
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
100,000
-13.94%
|
$1,100,000
$11.65 P/Share
|
|
Oct 21
2024
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+12.23%
|
$300,000
$3.85 P/Share
|
|
Oct 20
2024
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.06%
|
$120,395
$11.92 P/Share
|
|
Oct 20
2024
|
Rakhi Kumar Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
956
-0.46%
|
$10,516
$11.92 P/Share
|
|
Oct 20
2024
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-1.74%
|
$120,395
$11.92 P/Share
|
|
Sep 28
2024
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,340
-0.83%
|
$25,740
$11.48 P/Share
|
|
Sep 26
2024
|
Qvt Financial LP |
SELL
Open market or private sale
|
Indirect |
876,000
-3.8%
|
$9,636,000
$11.82 P/Share
|
Last 12 Months Summary
Buy / Acquisition
40.4M
Shares
From
15
Insiders
| Grant, award, or other acquisition | 36.4M shares |
|---|---|
| Exercise of conversion of derivative security | 4.01M shares |
Sell / Disposition
139M
Shares
From
28
Insiders
| Payment of exercise price or tax liability | 1.07M shares |
|---|---|
| Other acquisition or disposition | 126M shares |
| Open market or private sale | 11.8M shares |
| Grant, award, or other acquisition | 38.7K shares |